An Engineered Synthetic Biologic Protects Against Clostridium difficile Infection

Morbidity and mortality attributed to Clostridium difficile infection (CDI) have increased over the past 20 years. Currently, antibiotics are the only US FDA-approved treatment for primary C. difficile infection, and these are, ironically, associated with disease relapse and the threat of burgeoning...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Microbiol
Auteurs principaux: Vedantam, Gayatri, Kochanowsky, Joshua, Lindsey, Jason, Mallozzi, Michael, Roxas, Jennifer Lising, Adamson, Chelsea, Anwar, Farhan, Clark, Andrew, Claus-Walker, Rachel, Mansoor, Asad, McQuade, Rebecca, Monasky, Ross Calvin, Ramamurthy, Shylaja, Roxas, Bryan, Viswanathan, V. K.
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2018
Sujets:
Microbiology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6134020/
https://ncbi.nlm.nih.gov/pubmed/30233548
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmicb.2018.02080
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires